Valo Therapeutics Announces Positive Interim Results from PeptiCRAd-1 Phase 1 Clinical Trial
Helsinki, Finland, 30 June, 2025 – Valo Therapeutics Oy (ValoTx), a clinical-stage biotechnology company developing novel oncolytic virus-based cancer immunotherapies, today announced encouraging interim results from its ongoing Phase 1 clinical trial, START (Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer) — ClinicalTrials.gov ID: NCT05492682.
PeptiCRAd-1 combines tumor-targeting adenoviruses with tumor-specific peptides to stimulate both innate and adaptive immune responses against cancer.
Key Interim Findings (Cohort 1):
- Well tolerated, with no serious treatment-related adverse reactions.
- Immune activation observed in the majority of patients.
- T-cell responses against tumor antigens detected.
- Evidence of tumor infiltration by immune cells.
- Clinical responses seen in 2 out of 5 patients, with disease control in 3.
“These early results demonstrate that PeptiCRAd-1 is well tolerated and has the potential to safely activate the immune system,” said Charlotta Backman, VP of Clinical Operations and Regulatory Affairs. “We are particularly encouraged by the robust immune activation and the early signs of anti-tumor activity,” added Sari Pesonen, Chief Scientific Officer of ValoTx.
“We’re excited by the signal and look forward to expanding our data set with Cohort 2.” said Marcella Origgi, CEO of ValoTx.
Next Steps
The trial continues with Cohort 2, which includes subcutaneous dosing to enhance immune activation. Ongoing immunomonitoring will support biomarker discovery and patient stratification.
About PeptiCRAd-1
PeptiCRAd-1 is an innovative platform that uses an oncolytic adenovirus coated with tumor antigens to turn the patient’s tumor into a vaccine-like immune stimulus, aiming to unlock durable responses across multiple solid tumors.
About Valo Therapeutics
ValoTx is a clinical-stage company developing next-generation cancer immunotherapies that combine viral vectors and peptide-based strategies. Its proprietary PeptiCRAd platform enables rapid, tumor-specific immune activation tailored to each patient. For more information see our website and follow us on LinkedIn.
Contact:
Dr Marcella Origgi, CEO
+39 3409196605
www.valotx.com